{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04026",
      "entity_text" : "pH3S10",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "uaz:UA-CLine-5317" ],
      "TissueType" : [ "tissuelist:TS-0416" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Consequently, the administration of AZD1152 to treat patients whose GBM are characterized by the unmethylated MGMT gene and a high level of pH3S10 (MGMT U / pH3S10 H) appears as a promising therapeutic alternative since these patients have a poor overall survival in response to the standard anti-GBM therapy (8.3 months in our study).",
  "reading_complete" : "2020-08-02T11:59:08Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T11:57:32Z",
  "trigger" : "level",
  "evidence" : [ "level of pH3S10" ],
  "pmc_id" : "4265745",
  "score" : 0
}